Bernard Antoine, Boidot Romain, Végran Frédérique
Team CAdIR, CRI INSERM UMR1231 "Lipids, Nutrition and Cancer'', 21000 Dijon, France.
Faculté des Sciences de Santé, Université Bourgogne Franche-Comté, 21000 Dijon, France.
Cancers (Basel). 2022 Mar 28;14(7):1726. doi: 10.3390/cancers14071726.
Splicing is a phenomenon enabling the excision of introns from pre-mRNA to give rise to mature mRNA. All the 20,000 genes of the human genome are concerned by this mechanism. Nevertheless, it is estimated that the proteome is composed of more than 100,000 proteins. How to go from 20,000 genes to more than 100,000 proteins? Alternative splicing (AS) is in charge of this diversity of proteins. AS which is found in most of the cells of an organism, participates in normal cells and in particular in immune cells, in the regulation of cellular behavior. In cancer, AS is highly dysregulated and involved in almost all of the hallmarks that characterize tumor cells. In view of the close link that exists between tumors and the immune system, we present in this review the literature relating to alternative splicing and immunotherapy. We also provide a global but not exhaustive view of AS in the immune system and tumor cells linked to the events that can lead to AS dysregulation in tumors.
剪接是一种能从信使核糖核酸前体中切除内含子从而产生成熟信使核糖核酸的现象。人类基因组中的所有20000个基因都涉及这一机制。然而，据估计蛋白质组由超过100000种蛋白质组成。如何从20000个基因产生超过100000种蛋白质呢？可变剪接负责这种蛋白质多样性。可变剪接存在于生物体的大多数细胞中，参与正常细胞尤其是免疫细胞的细胞行为调控。在癌症中，可变剪接受高度失调影响，几乎涉及肿瘤细胞所有的特征。鉴于肿瘤与免疫系统之间存在的紧密联系，我们在本综述中呈现与可变剪接和免疫治疗相关的文献。我们还提供了关于可变剪接在免疫系统和肿瘤细胞中的整体但非详尽的观点，这些观点与可能导致肿瘤中可变剪接失调的事件相关。
